Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide injection combined with hypofractionated radiotherapy for brain metastases
ChiCTR1900027968Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Dec 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in brain metastases, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Objective response rate. Started Dec 2019; status: recruiting.
02
Drugs
temozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on ChiCTR1900027968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027968.